Erasca (ERAS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 26, 2026, to be held virtually for shareholders of record as of April 27, 2026.
Proxy materials, including the notice, proxy statement, and annual report or Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Shareholders will vote to elect three Class II directors for a three-year term expiring at the 2029 annual meeting.
Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is on the agenda.
Additional business may be transacted as appropriate during the meeting.
Board of directors and corporate governance
Nominees for Class II director positions are Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.
The board recommends a vote in favor of all director nominees and the auditor ratification.
Latest events from Erasca
- Virtual annual meeting to elect directors, ratify auditor, and highlight governance and ESG practices.ERAS
Proxy filing28 Apr 2026 - ERAS-0015 shows high response rates and favorable safety in RAS-mutated solid tumors.ERAS
Study result28 Apr 2026 - Advancing best-in-class RAS/MAPK inhibitors with strong data and major milestones ahead.ERAS
Corporate presentation22 Apr 2026 - Clinical advances and robust financing position support long-term RAS therapy development.ERAS
Q4 202512 Mar 2026 - Lead RAS-targeted therapies show strong early data, with major trial updates expected in 2024.ERAS
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Early clinical data show promising efficacy and safety for next-generation pan-RAS and pan-KRAS inhibitors.ERAS
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Advancing innovative RAS/MAPK-targeted therapies with strong financial backing and pivotal trials.ERAS
2024 Cantor Fitzgerald Global Healthcare Conference3 Feb 2026 - Refocused RAS/MAPK pipeline, strong clinical progress, and cash runway support key milestones to 2027.ERAS
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Advancing RAS-targeted therapies with pivotal trials and strong preclinical results.ERAS
Jefferies 2024 Global Healthcare Conference1 Feb 2026